drugset / Trial / NCT06593210
RSV Vaccine in Transplant Recipients
Phase 3
Active not recruiting
100 enrolled
University Health Network, Toronto
The Physicians' Services Incorporated Foundation · collabUniversity of British Columbia · collab
NaSingle-groupOpen-labelPrevention
Summary
Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral and cellular immunity. Participants will be followed for adverse reaction, hospitalization, RSV breakthrough infection, graft rejection or graft versus host disease. This study has Health Canada and UHN REB approval.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RSVPreF3 | Vaccine | — | — |